Top

Coronary Artery Disease

March 28, 2012 by · Comments Off on Coronary Artery Disease 

Coronary Artery Disease, Mount Sinai School of Medicine researchers presented 86 abstracts and plenary sessions at the American College of Cardiology’s (ACC) 61st Annual Scientific Session, including ground-breaking research on aggressive statin therapy, the prevalence of unrecognized cardiovascular disease symptoms in women, and morbidity associated with non-adherence to medication after stent implantation. The meeting took place March 23-27, 2012 in Chicago.

Mount Sinai Researchers Show Aggressive Statin Regimen Reduces Fat Content in Coronary Blockage That Can Lead to Acute Thrombosis: Results from the YELLOW Trial

Of 87 patients enrolled in a Mount Sinai trial, half were treated with an aggressive regimen (40 mg) of Rosuvastatin, and the other half received standard lipid therapy. After seven weeks, the group that took Rosuvastatin displayed a 22 percent reduction in the amount of fat in the blockage, while the group with standard lipid therapy showed no significant changes.

“This study provides new scientific information documenting the beneficial effects of aggressive lipid lowering therapy in high-risk patients with coronary artery disease,” said Annapoorna Kini, MD, Director of the Cardiac Catheterization Laboratory and Professor of Medicine at Mount Sinai. “Furthermore, the YELLOW trial opens new avenues for evaluating the response of novel therapies in men and women in the United States and abroad.”

Mount Sinai-Led Study Finds Cardiovascular Disease Screening of 3,000 Women in OB/GYN Clinics Identifies Risk Factors and Symptoms

A multicenter study of 3,000 women in OB/GYN clinics across the United States, found that 87 percent had unrecognized cardiovascular disease risk factors and 42 percent had symptoms. More than half of women with no primary care provider were unaware that their cholesterol and weight put them at risk.

Bottom